Macroprolactinomas Cause LOW Cortisol (Secondary Adrenal Insufficiency)
Macroprolactinomas lead to low cortisol levels through secondary adrenal insufficiency, not high cortisol. This occurs when the tumor mass compresses normal pituitary tissue, disrupting ACTH secretion and resulting in inadequate cortisol production.
Mechanism and Prevalence
The mass effect from macroprolactinomas damages the hypothalamic-pituitary-adrenal (HPA) axis, causing central hypocortisolism. The prevalence of secondary adrenal insufficiency correlates directly with tumor size:
- 10-19 mm tumors: 0% have hypocortisolism
- 20-39 mm tumors: 6.9% have hypocortisolism
- ≥40 mm tumors: 33.3% have hypocortisolism 1
Recent multicenter data confirms that approximately 52-57% of patients with macroprolactinomas present with ACTH deficiency at diagnosis 2. Another study found that 8.3% of all prolactinoma patients have secondary adrenal insufficiency, with tumor size being the only independent predictor (optimal cut-off: 17 mm) 3.
Clinical Presentation
Critical pitfall: The cortisol deficiency can be severe and life-threatening. Patients may present with:
- Severe hyponatremia (from inappropriate vasopressin secretion)
- Nausea, vomiting, anorexia
- Fatigue and weakness
- Hypotension
- Weight loss
One case report documented a patient with giant macroprolactinoma presenting with severe hyponatremia and biologically inactive circulating ACTH, requiring hydrocortisone replacement to normalize sodium levels 4.
Diagnostic Considerations
Important caveat: Basal ACTH levels may appear normal despite true adrenal insufficiency. The biological activity of ACTH may be impaired even when levels seem adequate 4. Morning cortisol < 80.8 µg/L strongly suggests CAI (95.2% specificity), while > 144 µg/L makes it unlikely 5.
Recovery After Treatment
Both medical (dopamine agonists) and surgical treatment allow for recovery of adrenal function, though recovery is incomplete in many patients:
- 55-60% of patients with ACTH deficiency recover after treatment 2
- Larger initial tumor size is a significant negative predictor of recovery from all hormone deficiencies 2, 3
- Recovery rates are higher in microadenomas (100%) versus macroadenomas (63%) 3
The adrenal axis shows relatively good recovery potential compared to the thyroid axis, which recovers in only 28-31% of cases 2.
Clinical Algorithm
- All macroprolactinomas ≥17 mm: Screen for secondary adrenal insufficiency with morning cortisol
- Morning cortisol ≤80.8 µg/L: Presume CAI and initiate hydrocortisone replacement
- Morning cortisol 80.8-144 µg/L: Perform ACTH stimulation testing
- Morning cortisol >144 µg/L: CAI unlikely, but reassess if symptoms develop
- Monitor during treatment: Reassess pituitary function as tumor shrinks, as many patients recover
Management warning: When initiating hydrocortisone in patients with prolonged untreated adrenal insufficiency, monitor closely for osmotic demyelination syndrome (from rapid sodium correction) and refeeding syndrome 6. Adjust plasma osmolality carefully and consider desmopressin if needed.